UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
April 7, 2016
Date of Report (Date of earliest event reported)
INVIVO THERAPEUTICS HOLDINGS CORP.
(Exact Name of Registrant as Specified in Charter)
|
Nevada |
|
001-37350 |
|
36-4528166 |
|
(State or Other |
|
(Commission File Number) |
|
(IRS Employer |
|
Jurisdiction of Incorporation) |
|
|
|
Identification No.) |
One Kendall Square, Suite B14402
Cambridge, Massachusetts 02139
(Address of Principal Executive Offices) (Zip Code)
(617) 863-5500
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 7, 2016, John A. McCarthy, Jr. informed the Board of Directors of InVivo Therapeutics Holdings Corp. (the “Company”) of his intention not to stand for re-election as a director at the Company’s 2016 Annual Meeting of Stockholders. Mr. McCarthy is departing to devote more time to his role as Chief Executive Officer and a director of ZS Genetics, Inc. as well as his other business ventures. Mr. McCarthy will continue to serve as a director of the Company until the expiration of his term at the conclusion of the Company’s 2016 Annual Meeting of Stockholders.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
INVIVO THERAPEUTICS HOLDINGS CORP. | |
|
|
|
|
| |
|
Date: April 12, 2016 |
|
By: |
/s/ Tamara Joseph | |
|
|
|
|
Name: |
Tamara Joseph |
|
|
|
|
Title: |
SVP, General Counsel & Chief Compliance Officer |